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Welcome to this special issue of PPAR Research, PPARs:
A Double-Edged Sword in Cancer Therapy. Peroxisome
Proliferator-Activated Receptors (PPARs) are a family of
pleiotropic transcription factors that play central roles in
cell metabolism and regulation of inﬂammation. Cancer
is thought to be the uncontrolled clonal evolution and
expansion of a mutated cell [1]. What is the connection
between PPARs and cancer? The theme of this special issue
reﬂects the impressive conﬂuence of two originally separate
streams of investigation: PPARs and cancer research. Despite
the multitude of points of intersection between PPARs and
neoplasia, and associated unresolved paradoxes, the link
between PPARs and tumors is not yet widely appreciated
amongspecialistsineitherﬁeld.However,overthepastyears,
investigators who cross these ﬁelds have unearthed a myriad
of remarkable connections.
In view of the multiple links between PPARs and cancer,
perhapsepitomizingthepleiotropyofthebiologicaleﬀectsof
PPARs, this special issue contains an unusually large number
of excellent contributions. This large volume may also reﬂect
the increasing recognition of PPARs as a key player in cancer.
To help guide the readers, we have organized the articles, in
a departure from tradition, not according to the subtypes
PPARα, δ/β and γ, but instead, broadly in Sections 1–
6. Section 1 contains reviews that oﬀer a comprehensive
overview on PPARs’ eﬀects in cancer and on the more
established role of PPARγ in cancer therapy. This is followed
by Sections 2, 3, and 4 which have articles that discuss the
following three key questions.
We close our special issue with Sections 5 and 6, which focus
on PPAR ligand-based cancer therapies and the molecular
mechanisms through which these ligands may act.
(1) We start with ﬁve reviews that provide the necessary
background on structure and physiology of PPARs with
an emphasis on their role in cancer. One of these reviews
focuses on PPARγ, which historically has been studied
most intensely in conjunction with cancer. Notably, the
therapeutic potential of PPARγ agonists has been evaluated
in clinical trials for liposarcoma and prostate cancer. In fact,
38 out of a total of 56 articles in this issue focus on PPARγ.
(2) We continue with the ﬁrst key question: Do PPARs
promote or inhibit cancer? The opposite directions of
observed PPAR eﬀects on cancer—which gave this special
issue its title—cannot be addressed in a straightforward
manner. This is not because of ambiguous observations but
(what makes it interesting) because the observed eﬀects of
PPARontumorshavebeenclear—cutandpowerfulineither
direction—either stimulating or suppressing tumors. That
PPARs act as a “double-edged sword” may not come as a
surprise to veterans of PPAR research who appreciate their
pleiotropic eﬀects. While PPARα was the ﬁrst PPAR to be
associatedwithtumorigenesis,theemergingawarenessofthe
PPARγ-cancer connection is evidenced by the fact that 4 out
of 7 reviews in this issue focus on PPARγ.
(3) While much attention has been devoted to deter-
mining whether PPARs are friend or foe of tumors, our
second question is also of fundamental signiﬁcance:I s
PPAR’s role in tumor growth mediated by cell autonomous
or by noncell autonomous mechanisms? From the perspective
of PPAR investigators, this question may arise naturally
because PPARs regulate intracellular processes, including
proliferation,apoptosis,anddiﬀerentiationaswellasinﬂam-
matory processes through the control of mediators in cell-
cell communication. In cancer biology this dualism has2 PPAR Research
deeper roots. It is the subject of a major paradigm shift that
has occurred over the past decade in cancer research. The
simple notion, unquestioned for decades, that cancer is a
cell-autonomous disease, driven by mutation and selection
for fast growing and increasingly malignant cell clones, has
yielded to the more encompassing view that cancer is also
a nonautonomous disease, requiring the support from the
“tissue microenvironment” in the “tumor bed”.
It took many years to overcome the picture of cancer
cell autonomy aﬀorded by cellular oncogenes. It began with
a simple idea that had far-reaching consequences. Judah
Folkman proposed in 1972, against all conventional wisdom,
that tumor growth required neovascularization, and that
such “tumor angiogenesis” was induced by soluble factors
produced by the tumor. We dedicate this special issue to
Dr. Folkman (1933–2008), our teacher and mentor, who has
opened the world’s eye to the tissue context of tumors. His
arduous uphill battle against the established paradigm of
cell-autonomous growth, although focused on angiogenesis,
has shined the ﬁrst beam of light on the role of the host
microenvironment which was hidden in the shadow of the
quest for mutations that establish the oncogenic pathways in
the cancer cell. Dr. Folkman’s persistence paved the path to
theacceptanceoftheactiveroleofnonneoplastic,“host”cells
in the tumor microenvironment. In this generalization of the
concept of tumor angiogenesis, it is now ﬁrmly established
that the tumor stroma is comprised a variety of cells that
are essential for tumor growth, including “tumor associated
ﬁbroblasts”, various inﬂammatory cells, and the pericytes
around the tumor endothelium.
Much as cancer research was initially focused on the
tumor parenchyma, the ﬁrst connection between PPARα
and tumorigenesis was also directed at understanding how
prolonged PPARα activation by its ligands induces hepa-
tocarcinogenesis in rodents by altering liver cell function
[2]. However, mirroring the development in tumor biology,
attention soon turned toward the eﬀects of PPAR on the
tumor microenvironment. In this issue, ten articles discuss
the modulation of the tumor stroma by PPARs. Five of these
reviewsdiscusstheireﬀectsonthetumorendothelium,while
the other ﬁve focus on the inﬂammatory compartment.
(4) The third major question addressed in this issue
refers to the tumor-inducing or inhibiting eﬀects of PPAR
ligands: are their activities on tumors mediated by their
nominal targets, the nuclear receptors, or do they act in
a PPAR-independent manner? This matter is complicated
by the fact that both PPAR agonists and antagonists can
inhibit tumor progression. Six reviews provide an overview
of the use of PPAR agonists and their “oﬀ-target” eﬀects in
various cancer therapies. We have also included one original
researcharticleonhowrosiglitazoneinhibitsbothtumorand
endothelial cells via receptor dependent and independent
mechanisms.
(5) The vast majority of PPAR research in the context of
cancer focuses on the use of ligands in anticancer therapies.
Thus, we dedicate the next section to articles that review
preclinical and clinical studies of the use of PPARα and
PPARγ ligands in a variety of cancer models, including
combinatorial therapy.
(6) The last section of this special issue contains arti-
cles that review the molecular mechanisms through which
PPARs, or their ligands, modulate tumor growth. There is
an additional original research article in this section on how
rosiglitazone inhibits tumor cell proliferation by interfering
with IGF-IR signaling.
We hope you will ﬁnd these articles informative. Clearly,
much work lies ahead if we are to unravel the mysteries
behind the double edged-sword nature of PPARs. This
special issue describes the problem from many angles, and
in doing so it reveals the gaps in our knowledge. Thus, rather
than providing a unifying answer, it may hopefully inspire
you to further research.
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